started · updated
GLP-1 medications show broad health benefits despite risks
GLP-1 receptor agonists, such as Ozempic, Wegovy, and Mounjaro, are demonstrating medical utility far beyond their original indications for Type 2 diabetes and obesity. Research indicates these drugs may offer cardiovascular protection, kidney support, reduction in liver fat, and potential benefits for sleep apnea, neuroprotection, and certain obesity-related cancers.
However, medical experts and recent reports emphasize significant risks and side effects. Common issues include gastrointestinal distress, such as diarrhea and vomiting, as well as more serious concerns like pancreatitis, vision disturbances, and kidney problems. Dental professionals have also noted “Ozempic teeth,” a colloquial term for xerostomia (dry mouth) caused by decreased saliva production, which can lead to severe dental decay.
Furthermore, clinical data suggests that the benefits may diminish upon discontinuation. A study of over 132,000 American veterans found that while GLP-1 therapy reduced the risk of heart attack, stroke, or death by 18 percent, these protective effects gradually fade once treatment is stopped. This poses challenges regarding weight regain and the long-term management of chronic conditions.
Entities
American Diabetes Association · FDA · Harvard Medical School · Science · Washington University in St. Louis · Ziyad Al-Aly